eligibility_summary
Eligible: Adults (≥18) with symptomatic MM that previously achieved ≥PR and is now relapsed/relapsed‑refractory, refractory to ≥1 prior IMiD and/or PI line (≥2 cycles). Prior anti‑CD38 allowed if ≥PR and >6 months since. Must consent, adhere to visits, and be high‑risk (IMWG frail ≥2, KPS ≤70, or clinician‑judged due to ≥G3 toxicity or ≥2 prior dose reductions). Exclude: therapy <2 wks, prior pomalidomide, any mAb <30 d, anti‑CD38 <6 mo, ASCT <12 wks, or unfit for any systemic therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05911321 tests isatuximab + low‑dose pomalidomide + dexamethasone (Isa‑Pd) in elderly/frail relapsed/refractory multiple myeloma. Drugs/mechanisms: Isatuximab—anti‑CD38 IgG1 monoclonal antibody immunotherapy, induces ADCC, ADCP, CDC, and direct apoptosis of CD38+ myeloma cells and inhibits CD38 ectoenzyme–mediated immunosuppression. Pomalidomide—oral immunomodulatory drug (IMiD), binds cereblon (CRL4CRBN), degrades IKZF1/IKZF3, downregulates IRF4/MYC, is anti‑angiogenic, and enhances T/NK‑cell activity. Dexamethasone—oral corticosteroid, glucocorticoid receptor agonist causing lymphoid/plasma‑cell apoptosis and cytokine suppression. Targets/pathways: CD38+ malignant plasma cells, NK/T‑cell effector pathways, cereblon E3 ubiquitin ligase pathway, glucocorticoid receptor signaling and tumor‑microenvironment cytokines.